Ragnar Lunde

Learn More
Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of osteoporosis. However, the prevalence, correlates and effectiveness of treatment of osteoporosis in COPD patients remain unclear. We performed a systematic review of the literature to answer three questions. 1) What is the prevalence of osteoporosis in COPD? 2) What are(More)
RATIONALE Chronic obstructive pulmonary disease (COPD) patients are at increased risk of osteoporosis. Osteoporosis is under diagnosed and under treated in these patients and the underlying mechanisms remain unclear. To date, screening recommendations for osteoporosis in COPD patients are not available. OBJECTIVES To examine the prevalence of drug(More)
PURPOSE We previously showed that individualized radiation dose escalation based on normal tissue constraints would allow safe administration of high radiation doses with low complication rate. Here, we report the mature results of a prospective, single-arm study that used this individualized tolerable dose approach. PATIENTS AND METHODS In total, 166(More)
BACKGROUND Sequential chemotherapy and individualised accelerated radiotherapy (INDAR) has been shown to be effective in non-small cell lung cancer (NSCLC), allowing delivering of high biological doses. We therefore performed a phase II trial (clinicaltrials.gov; NCT00572325) investigating the same strategy in concurrent chemo-radiation in stage III NSCLC.(More)
We present a patient with progressive dysphagia and shortness of breath due to a right aortic arch with aberrant left subclavian artery that became symptomatic in adulthood. Diagnosis was made after a delay because the possibility of a congenital anomaly was not considered when the patient presented with dysphagia. A review is given of the incidence,(More)
BACKGROUND Individualised, isotoxic, accelerated radiotherapy (INDAR) allows the delivery of high biological radiation doses, but the long-term survival associated with this approach is unknown. METHODS Patients with stage III NSCLC in the Netherlands Cancer Registry/Limburg from January 1, 2002 to December 31, 2008 were included. RESULTS Patients(More)
PURPOSE In non-small cell lung cancer, gross tumor volume (GTV) influences survival more than other risk factors. This could also apply to small cell lung cancer. METHODS AND MATERIALS Analysis of our prospective database with stage I to III SCLC patients referred for concurrent chemo radiation therapy. Standard treatment was 45 Gy in 1.5-Gy fractions(More)
BACKGROUND There is little data on the survival of elderly patients with stage III non-small cell lung cancer (NSCLC). METHODS Patients with stage III NSCLC in the Netherlands Cancer Registry/Limburg from January 1, 2002 to December 31, 2008 were included. FINDINGS One thousand and two patients with stage III were diagnosed, of which 237 were 75 years(More)
BACKGROUND Non-small cell lung cancer (NSCLC) stage T4N0-1 or single nodal station IIIA-N2 are two stage III sub-groups for which the outcome of non-surgical therapy is not well known. We investigated the results of individualised isotoxic accelerated radiotherapy (INDAR) and chemotherapy in this setting. METHODS Analysis of NSCLC patients included in 2(More)
e19525 Background: The medical practice with epoetin alfa (Eprex) treatment (ET) for chemotherapy-induced anaemia (CIA) in the Netherlands was evaluated with regards to safety and efficacy in this observational study enrolling 1927 patients (pts) from 2005 to 2009. METHODS Eligible pts were ≥18 years and diagnosed with a solid tumour, multiple myeloma or(More)
  • 1